Adjusted HR for
PC-specific mortality was 0.76 (95% CI, 0.64 to 0.89)
for each additional 6 months of metformin use.
The association with all-cause mortality was also significant but
declined
over time from an HR of 0.76 in the first 6
months to 0.93 between 24 and 30 months. There was no relationship
between cumulative
use of other antidiabetic drugs and either
outcome... Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and
PC-specific mortality among diabetic men.
Generally we know that metformin is used in Type 2 Diabetes and that in addition Type 2 Diabetics are obese. We also know that they generally consume high carbs and often have high oxidants resulting therefrom. Metformin increases insulin secretion somewhat and thus may drive down this process. This of course is speculation, logically somewhat correct, but of interest.
Posts
